BioBridgeX
Log inCompare quotes
Modality

mRNA / saRNA CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing the mRNA / saRNA modality means contracting specialist CRO and CDMO partners across construct design and sequence optimization, in vitro transcription, capping and tailing, purification, lipid nanoparticle (LNP) encapsulation, RNA-specific analytics, IND-enabling tox, and GMP clinical supply. On BioBridgeX, buyers source and compare qualified mRNA / saRNA suppliers as the neutral marketplace: free for buyers, contract directly with suppliers.

mRNA / saRNA CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing mRNA / saRNA CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture a mRNA / saRNA drug?

An mRNA or self-amplifying RNA program is a chain of fairly distinct capabilities, and the modality rewards teams that know where one specialist's work ends and the next begins. It starts at the bench with sequence and construct design: codon optimization, the untranslated regions that drive translation, the cap and poly-A strategy, and for saRNA the replicase machinery that lets a smaller dose self-amplify inside the cell. Most of this early design and screening work is research-grade, run by a discovery CRO or in-house, and it sets the quality of everything downstream.

From there the work moves into CMC, which is where mRNA differs most from a small molecule or an antibody. The drug substance is made by in vitro transcription (IVT): an RNA polymerase reads a linearized DNA template, the RNA is capped (co-transcriptionally with a cap analog or enzymatically) and tailed, then purified to strip out template DNA, double-stranded RNA byproducts, residual NTPs, and enzyme. That plasmid template is a manufactured starting material in its own right, frequently the real item on the critical path. Naked RNA degrades in minutes and barely crosses a cell membrane, so almost every program pairs the RNA drug substance with LNP encapsulation (an ionizable lipid, a helper phospholipid, cholesterol, and a PEG-lipid mixed with the payload) as the drug-product step.

This is where specialist mRNA / saRNA CDMOs separate from generalists. A shop that runs CHO antibody campaigns every week is not set up for IVT, oligo-dT affinity capture, or dsRNA control, and the analytics are their own discipline: RNA integrity by capillary gel electrophoresis, capping efficiency by LC-MS, poly-A tail characterization, dsRNA quantitation, residual template DNA, and sequence confirmation. saRNA adds its own wrinkles, since the construct is longer and the replicon has to stay intact. RNA is one of the faster modalities to manufacture once the upstream pieces are ready, which is exactly why it carried the COVID vaccines, but that speed assumes the template, the cap strategy, and the validated methods already exist. Treating LNP and analytics as an afterthought is the usual reason an otherwise fast program stalls between suppliers.

How do you choose a CRO or CDMO for mRNA / saRNA?

The honest filter is fit to your construct and your stage, not the size of the facility. A vaccine-scale mRNA CDMO can be over-built for a rare-disease program that needs a few grams, and a supplier strong on standard mRNA may be a beginner at self-amplifying or circular RNA. Score two or three suppliers against the same written scope (sequence type, quantity, quality grade, cap strategy, whether LNP is included), and weigh the analytical and regulatory track record at least as heavily as the per-gram price. The checklist below covers the attributes that actually separate a clean engagement from a painful one.

  • Relevant platform and track record: real, completed work in your specific construct (standard modified-nucleotide mRNA, saRNA, circular RNA) and your application (vaccine, protein replacement, in vivo editing), not a generic RNA claim. saRNA in particular needs a supplier who has handled the longer transcript and the replicon.
  • GxP grade and analytical capability for this modality: confirm the actual grade on offer (research, non-GMP engineering, or full GMP under 21 CFR Part 211 or EU GMP) and whether the RNA-specific methods (integrity, capping efficiency, dsRNA, residual DNA template, poly-A tail) are qualified or validated rather than improvised per batch.
  • Capacity and scale: a scale you can grow into, from milligram tox batches through gram-scale clinical supply, with a realistic slot. Ask where the critical path actually sits, usually template linearization, cap-analog and raw-material lead times, and method readiness rather than the IVT reaction itself.
  • LNP and drug-product scope: whether the supplier encapsulates to LNP and fill-finishes in-house or stops at purified drug substance, and how the plasmid template is sourced and qualified, so you know exactly where the handoffs occur and whether a tech transfer is coming.
  • Regulatory experience: which agencies the site has filed with (FDA, EMA, PMDA), recent inspection history, raw-material traceability, and whether they can author the CMC sections your IND needs. The test article in your GLP tox study has to match the clinical formulation, so the process should be locked before the pivotal studies start.
  • IP and confidentiality: who owns process improvements made on your program, freedom-to-operate on any licensed capping or proprietary-lipid technology you would be locked into, and clean tech-transfer terms if you move the process later.

Frequently asked questions

What is the difference between mRNA and self-amplifying RNA (saRNA)?
Conventional mRNA delivers the coding sequence for your protein and is translated directly, so the protein level tracks the dose you gave. Self-amplifying RNA carries the same antigen or protein sequence plus a viral replicase that copies the RNA inside the cell, so a much smaller dose can produce a comparable or longer protein output. For manufacturing, saRNA means a longer transcript and an intact replicon to characterize, which changes the purification train and the integrity analytics. A CDMO that is fluent in standard mRNA is not automatically set up for saRNA, so confirm completed saRNA work specifically rather than a general RNA capability.
What is the difference between mRNA drug substance and the LNP drug product?
The drug substance is the purified RNA molecule itself, made by in vitro transcription, then capped, tailed, and cleaned up. The drug product is that RNA encapsulated in a lipid nanoparticle (LNP) and filled into vials or syringes ready to dose. Naked mRNA degrades fast and enters cells poorly, so almost every program needs the LNP step. Some CDMOs make both the RNA and the LNP product under one roof; others stop at purified drug substance and hand off to a separate LNP or fill-finish partner. Confirm where your supplier's scope ends before you sign, because that handoff is where RNA programs most often lose time.
Do I need a separate supplier to make the DNA template?
Often, yes. The IVT reaction reads from a linearized DNA template, usually a plasmid, and that plasmid is itself a manufactured starting material (plasmid DNA manufacturing) with its own quality grade and lead time. Some RNA CDMOs make or source the template in-house and linearize it for you; others expect you to supply qualified plasmid. The template is frequently the real item on the critical path, so settle early who is making it, to what grade, and how long it takes. GMP RNA usually needs a documented, suitably qualified template behind it.
What quality grade do I need: research, GMP-like, or full GMP?
It depends on what the material is for. Early tox and proof-of-concept work can usually run on research-grade or engineering-grade RNA, which is faster and cheaper. Material that supports an IND and first-in-human dosing has to be made under GMP (21 CFR Part 211 in the US, EU GMP in Europe), with batch records, a defined specification, release testing, and stability data. The mistake runs in both directions: paying GMP prices and timelines for an exploratory batch nobody will file, or assuming a research-grade lot will satisfy a regulator. Decide the grade per batch before you scope the work.
Which analytical tests should an mRNA / saRNA CDMO run on my batches?
At minimum, expect RNA integrity and intactness (capillary gel electrophoresis or fragment analysis), capping efficiency (often by LC-MS), poly-A tail characterization, double-stranded RNA quantitation, residual DNA template and residual protein, endotoxin, appearance and concentration, and sequence confirmation. dsRNA and residual template matter because they drive innate-immune reactogenicity and have to be controlled. For saRNA, integrity of the full-length replicon is an added concern. A capable supplier will have these methods qualified or validated, and the depth of this analytical package is usually where real cost and timeline differences between quotes show up.
How does BioBridgeX coordinate RNA drug substance, LNP, and fill-finish across suppliers?
An mRNA or saRNA program frequently spans more than one supplier: a plasmid template source, the RNA drug-substance CDMO, an LNP formulation partner, and a fill-finish site, plus the IND-enabling tox CRO. BioBridgeX is a neutral marketplace, so you source and compare qualified suppliers for each step in one place and contract directly with the ones you choose. It is free for buyers, suppliers pay a flat 2% fee, and coverage runs across every indication and modality and the full lifecycle, so the same thread carries from clinical supply into commercial manufacturing.

Source mRNA / saRNA work with one contract

Compare transparent quotes from qualified mRNA / saRNA CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes